Search
Butylscopolamine
go.drugbank.com/drugs/DB09300ApprovedInvestigationalVet approvedIt is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. … It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms.
Mixtures: BIPASMIN COMPUESTO N, BIPASMIN COMPUESTO NSynonyms: N-butylscopolammonium, N-butylscopolammonium ionSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalby Alkermes Inc. … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnIt is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … Prosomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384].
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalThe prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubu...
Synonyms: 4-(N,N-Dipropylsulfamoyl)benzoesäure, 4-(Di-n-propylsulfamoyl)benzoesäureCategories: Preparations With No Effect on Uric Acid MetabolismOcrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalDeveloped by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. … [A31739] Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalIt works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. … [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323]
Salsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalIn contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. … Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticMolindone
go.drugbank.com/drugs/DB01618ApprovedSome electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283) … It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors.
Omega-3-acid ethyl esters
go.drugbank.com/drugs/DB09539ApprovedInvestigationalOmega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849].
Mixtures: Mi-Omega NFDextroamphetamine
go.drugbank.com/drugs/DB01576ApprovedIllicitInvestigationalDextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]